Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALISADE BIO, INC.PALI · Entity 5803 | Director | July 08, 2026 | July 10, 2026 |
| VivoSim Labs, INC.ONVO · Entity 8386 | Director | July 26, 2018 | July 30, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALISADE BIO, INC.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 461,904 |
Ending reported balance
After 2026-07-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-08 · Purchase · Acquired 20,000 · Balance 436,904 F1: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.98 to $2.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Row 2 · 2026-07-09 · Purchase · Acquired 25,000 · Balance 461,904 F2: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.9298 to $1.98. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.98 to $2.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.9298 to $1.98. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
VivoSim Labs, INC.
Report date July 26, 2018 · Filed July 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2028-07-26 | Direct | 45,550 |
Reported balance
After 2018-07-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-26 · Grant · Acquired 45,500 · Balance 45,550 F1: The option shares vest and become exercisable in full on the earlier of (i) July 26, 2019 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares vest and become exercisable in full on the earlier of (i) July 26, 2019 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Frazier Lifesciences Acquisition Corp
Report date November 22, 2022 · Filed November 23, 2022
Section 16 reporting ended · disclosed 2022-11-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-11-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-22 · Exercise / conversion · Disposed 30,000 · Balance 0 F1: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022.
Imago BioSciences, Inc.
Report date January 11, 2023 · Filed January 11, 2023
Section 16 reporting ended · disclosed 2023-01-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-01-11 transaction · row 1
1 source rowRow 1 · 2023-01-11 · Other · Disposed 850 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2030-03-30 | Direct | 0 |
Reported balance
After 2023-01-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-11 · Disposition to issuer · Disposed 114,075 · Balance 0 F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-07-14 | Direct | 0 |
Reported balance
After 2023-01-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-11 · Disposition to issuer · Disposed 23,809 · Balance 0 F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.65 · Expires 2032-05-31 | Direct | 0 |
Reported balance
After 2023-01-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-11 · Disposition to issuer · Disposed 11,904 · Balance 0 F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 10, 2026 22:14 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 25,000 | $1.96 | $48,900.00 |
DisclosureSEC source: 0001493152-26-032884 · ownership.xml · nonDerivative · entry 2 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 461,904 F2 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.9298 to $1.98. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 22:14 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 20,000 | $1.99 | $39,798.00 |
DisclosureSEC source: 0001493152-26-032884 · ownership.xml · nonDerivative · entry 1 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,904 F1 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.98 to $2.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 22:56 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 30,000 | $2.03 | $61,044.00 |
DisclosureSEC source: 0001493152-26-032563 · ownership.xml · nonDerivative · entry 2 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,904 F2 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.00 to $2.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 22:56 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 20,000 | $2.05 | $41,040.00 |
DisclosureSEC source: 0001493152-26-032563 · ownership.xml · nonDerivative · entry 1 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 386,904 F1 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.04 to $2.068. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 23:48 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 10,000 | $1.98 | $19,800.00 |
DisclosureSEC source: 0001493152-26-032229 · ownership.xml · nonDerivative · entry 2 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,904 F1 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.97 to $1.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 23:48 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 20,000 | $1.98 | $39,600.00 |
DisclosureSEC source: 0001493152-26-032229 · ownership.xml · nonDerivative · entry 1 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,904 F1 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.97 to $1.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2026 Filed Jun 18, 2026 20:10 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock | 336,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-029329 · ownership.xml · nonDerivative · entry 1 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,904 F1 · kind: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| January 11, 2023 Filed Jan 11, 2023 21:10 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,904 | Not disclosed Strike: $15.65 | Not disclosed |
DisclosureSEC source: 0000899243-23-001585 · doc4.xml · derivative · entry 4 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,904 shares Expires 2032-05-31 F1 · price: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. F1 · derivative.exercise_date: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. Read SEC document |
| January 11, 2023 Filed Jan 11, 2023 21:10 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,809 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0000899243-23-001585 · doc4.xml · derivative · entry 3 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,809 shares Expires 2031-07-14 F1 · price: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. F1 · derivative.exercise_date: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. Read SEC document |
| January 11, 2023 Filed Jan 11, 2023 21:10 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | Disposition to issuerStock Option (Right to Buy) · Derivative | 114,075 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0000899243-23-001585 · doc4.xml · derivative · entry 2 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 114,075 shares Expires 2030-03-30 F1 · price: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. F1 · derivative.exercise_date: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. Read SEC document |
| January 11, 2023 Filed Jan 11, 2023 21:10 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | OtherCommon Stock | 850 | $36.00 | $30,600.00 |
DisclosureSEC source: 0000899243-23-001585 · doc4.xml · nonDerivative · entry 1 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:25 UTC | Frazier Lifesciences Acquisition Corp FLAC · Entity 122080 | Exercise / conversionClass B Ordinary Shares · Derivative | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-036924 · doc4.xml · derivative · entry 1 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. F1 · price: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. F1 · derivative.exercise_date: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. F1 · derivative.expiration_date: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:41 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | GrantStock Option (Right to Buy) · Derivative | 11,904 | $0.00 Strike: $15.65 | $0.00 |
DisclosureSEC source: 0001567619-22-012293 · doc1.xml · derivative · entry 2 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual meeting in 2023 of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:09 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | GrantStock Option (Right to Buy) · Derivative | 23,809 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013639 · doc1.xml · derivative · entry 2 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,809 Underlying: Common Stock · 23,809 shares Expires 2031-07-14 F2 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares initially subject to the option will vest on each monthly anniversary measured from July 15, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:09 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | PurchaseCommon Stock | 850 | $16.00 | $13,600.00 |
DisclosureSEC source: 0001567619-21-013639 · doc1.xml · nonDerivative · entry 1 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 850 F1 · ownership.nature: Held by Stifel as custodian for the Bob Baltera IRA. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 20:51 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001209191-18-044417 · doc4.xml · derivative · entry 1 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,550 Underlying: Common Stock · 45,550 shares Expires 2028-07-26 F1 · derivative.exercise_date: The option shares vest and become exercisable in full on the earlier of (i) July 26, 2019 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 20:32 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 42,500 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001209191-17-050397 · doc4.xml · derivative · entry 1 Baltera Robert Jr. · CIK 0001536555 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2027-08-24 F1 · derivative.exercise_date: The option shares vest and become exercisable in full on the earlier of (i) August 24, 2018 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.